Compare DexCom, Inc. (DXCM) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Dentsply Sirona (XRAY) trades at $12.70, down 0.63% with bearish profitability metrics including negative net income margin and ROE. The stock shows mixed technical signals with bullish moving averages but overbought RSI levels. Recent earnings have consistently missed expectations, though the company maintains a 48.93% gross margin and is expanding its US distribution network with new partnerships and AI-enabled product launches.

While analyst consensus leans Hold with a $13.33 price target, the stock faces significant fundamental challenges including declining revenue, negative earnings, and rising debt-to-asset ratios. Near-term catalysts include the Q2 2026 earnings report and continued execution of the Return-to-Growth plan, but investors should weigh the high valuation multiples against persistent profitability concerns.